ArticleJournal of virology1999
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Excision of HIV-1 Provirus in Human Primary Cells with Nanocapsuled TALEN Proteins.ACS applied bio materials · 2025Article
- Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.Science (New York, N.Y.) · 2024Article
- Virus-like Particles: Measures and Biological Functions.Viruses · 2022Review
- Article
- Conflicting Selection Pressures Will Constrain Viral Escape from Interfering Particles: Principles for Designing Resistance-Proof Antivirals.PLoS computational biology · 2016Article
- Exploiting Genetic Interference for Antiviral Therapy.PLoS genetics · 2016Review
- Article
- The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth.The Journal of biological chemistry · 2014Article
- Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.NMR in biomedicine · 2014Article
- Reply to "Coadaptive stability of interfering particles with HIV-1 when there is an evolutionary conflict".Journal of virology · 2013Article
- Design requirements for interfering particles to maintain coadaptive stability with HIV-1.Journal of virology · 2013Article
- Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo.PloS one · 2012Article
- HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes.Virology · 2011Article
- Autonomous targeting of infectious superspreaders using engineered transmissible therapies.PLoS computational biology · 2011Article
- Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.AIDS (London, England) · 2010Article
- Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft.Cancer research · 2009Article
- Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2008Article
- Compensatory role of human immunodeficiency virus central polypurine tract sequence in kinetically disrupted reverse transcription.Journal of virology · 2008Article
- Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recently, gene therapy vectors based upon the human immunodeficiency virus type 1 (HIV-1) genome have been developed. Here, we create an HIV-1 vector which is defective for all HIV-1 genes, but which maintains cis-acting elements required for efficient packaging, infection, and expression. In T cells transduced by this vector, vector expression is low but efficiently induced following HIV-1 infection. Remarkably, although the HIV-1 vector does not contain specific anti-HIV-1 therapeutic genes, the presence of the vector alone is sufficient to inhibit the spread of HIV-1 infection. The mechanism of inhibition is likely to be at the level of competition for limiting substrates required for either efficient packaging or reverse transcription, thereby selecting against propagation of wild-type HIV-1. These results provide proof of a concept for potential application of a novel HIV-1 vector in HIV-1 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.